Odronextamab receives ema filing acceptance for treatment of relapsed/refractory follicular lymphoma and diffuse large b-cell lymphoma

Tarrytown, n.y., aug. 17, 2023 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the european medicines agency (ema) has accepted for review the marketing authorization application (maa) for odronextamab to treat adult patients with relapsed/refractory (r/r) follicular lymphoma (fl) or r/r diffuse large b-cell lymphoma (dlbcl), who have progressed after at least two prior systemic therapies. the ema previously granted odronextamab orphan drug designation for fl and dlbcl. odronextamab is an investigational cd20xcd3 bispecific antibody designed to bridge cd20 on cancer cells with cd3-expressing t cells to facilitate local t-cell activation and cancer-cell killing.
REGN Ratings Summary
REGN Quant Ranking